By Colin Kellaher 



  Eli Lilly & Co. Monday said the U.S. Food and Drug Administration approved the expanded use of Taltz for the treatment of active non-radiographic axial spondyloarthritis in patients with objective signs of inflammation. 


  The Indianapolis drug maker said Taltz is now approved to treat patients across the full axial spondyloarthritis spectrum, including ankylosing spondylitis, also known as radiographic axial spondyloarthritis. 


  Axial spondyloarthritis is a disease predominantly affecting the sacroiliac joints and the spine, resulting in chronic inflammatory back pain and fatigue. 


  Eli Lilly said the FDA approval is the fifth for Taltz, which the agency has also cleared for indications in moderate to severe plaque psoriasis and active psoriatic arthritis. 


  Write to Colin Kellaher at colin.kellaher@wsj.com